secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apimeds Pharmaceuticals US, Inc. (APUS)
CIK:        0001894525
Form:       8-K
Filed at:   2026-09-11T13:10:36+00:00
Accession:  0001213900-26-099002
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apimeds amends settlement to restructure board; appoints Chae director
----------------------------------------------------------------------

- On Sep 10, 2026, company amended settlement with Inscobee Parties, altering Board structure.
- Interim Board set to only Kogan, O'Donnell, Weintraub, and Chae; no removals without Menon/Inscobee consent.
- Post-conversion Board: 4 MindWave-nominated independents, 2 Menon nominees (incl. Menon), and Chae.
- Sungjoon Chae appointed to Board effective Sep 10, 2026; already Co-CEO since May 2026.
- Agreement is Delaware-governed; full text filed as Exhibit 10.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894525/000121390026099002/0001213900-26-099002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894525/000121390026099002/ea0305245-8k_apimeds.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-099002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer